Parkinson's Disease Clinical Trials

Showing 681-700 of 890 trials

Investigating Therapies for Freezing of Gait

NCT03065127

Freezing of gait (FOG) is arguably one of the most debilitating motor symptoms experienced by individuals with Parkinson's disease (PD). FOG may be caused by an overload of cognitive, limbic, and sensorimotor system activity in the basal ganglia. Therefore, the purpose of this study is to evaluate cognitive, limbic, and sensorimotor therapies in individuals with FOG. Participants in this study will undergo all three types of treatments in a randomized counterbalanced order. Each treatment will occur in 1 hour sessions, twice weekly for a period of 4 weeks.

Parkinson DiseaseGait Disorders, Neurologic

Sun Life Financial Movement Disorders Research and Rehabilitation Centre17 participantsStarted Feb 2017

Waterloo, Ontario, Canada

COMPLETEDPHASE1

Effect of Food on Opicapone

NCT03116308

The purpose of this study is to investigate the effect of food on the catechol-O-Methyltransferase (COMT) activity after repeated doses of opicapone (OPC, development code BIA 9-1067) in healthy subjects and to characterize the effects of food on the pharmacokinetics (PK) and tolerability of OPC after repeated doses.

Parkinson Disease

Bial - Portela C S.A.28 participantsStarted Nov 2014

Investigating Therapies for Freezing of Gait

Effect of Food on Opicapone

Related Searches

Cholinergic Nicotinic Receptors and Cognition in PD

The Effects of Treadmill Training With Visual and Auditory Cues on Gait Parameters in Parkinsonian Patients in Advanced Stages of Disease.

Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Effect of Food on BIA 6-512 (Trans-resveratrol)

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

Caffeine as a Therapy for Parkinson's Disease

Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

Effect of Levodopa on Postural Motor Learning in Parkinson Disease

Virtual Reality in Parkinson Disease

Expiratory Muscle Training for Persons With Neurodegenerative Disease

Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

Effects of the Mechanical Peripheral Stimulation for Parkinson's Disease Rehabilitation

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects